Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00814879 · ClinicalTrials.gov registry record · NA
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT00814879: Completed NA study, sponsored by Yale University.
NCT00814879 is a NA study that has completed, run by Yale University. The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00814879, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
This pilot study will provide data on the safety and efficacy of the combination of Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced subjects that have a suppressed HIV viral load on a Ritonavir (RTV) boosted Protease Inhibitor (PI) based regimen who are then switched to a regimen of RAL 400mg BID +ATV 300mg BID.
Primary Outcome
Virologic failure was defined by protocol as a plasma HIV RNA \>50 c/mL on 2 consecutive occasions \>7 days apart or \> 10 000 c/mL on one occasion (in the absence of an intercurrent infection or recent immunization).
Interventions
- DRUG Atazanavir
- DRUG Raltegravir
- OTHER Standard treatment regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-11 |
| Phase | NA |
What the finished NCT00814879 record still lists
NCT00814879 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Atazanavir is the first listed.
NCT00814879 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00814879 about?
NCT00814879 is a clinical study titled "Pilot Study of a Raltegravir Based NRTI Sparing Regimen". This pilot study will provide data on the safety and efficacy of the combination of Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced subjects that have a suppressed HIV viral load on a Ritonavir (RTV) boosted Protease Inhibitor (PI) based regimen who are ...
What is the current status of trial NCT00814879?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2009-05. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00814879?
The interventions under investigation include: Atazanavir (DRUG), Raltegravir (DRUG), Standard treatment regimen (OTHER).
Who is sponsoring clinical trial NCT00814879?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00814879's enrollment target sits among peer trials
60 1164th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia